Zydus gets emergency nod for ‘Virafin’ for COVID-19 treatment

Published On: Friday, April 23, 2021 | By: Team KnowMyStock

Zydus Cadila(Pharma company) today (23rd April 2021) received restricted Emergency use approval from India’s drug regulator for the use of Virafin, Pegylated Interferon alpha-2b (PegIFN) in treating moderate Covid-19 infection in adults. When administered early on during Covid, Virafin will help patients recover faster and avoid much of the complications, the company said in a statement. Virafin will be available on the prescription of a medical specialist for use in a hospital setup. “A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients,” the company said. In its Phase III clinical trials, the therapy had shown better clinical improvement in the patients suffering from Covid-19. "The drug ensures faster viral clearance and has several add-on advantages compared to other anti-viral agents”.

Closing Bell: Sensex gains 85 points, Nifty at 18755.90

Closing Bell:Sensex gains 418 points, Nifty at 18716.15

MARKET UPDATE: Sensex rose 135 points to 62761, and the NSE Nifty50 moved 40 points higher to 18,600

Closing Bell: Sensex down 223 points, Nifty at 18,563

MARKET UPDATE: Sensex surged over 100 points to trade around 62,962 levels, whereas Nifty50 climbed over 30 points to trade above 18,650 levels

MARKET UPDATE: Sensex gained over 50 points to trade around 63,228 levels, whereas Nifty50 traded marginally above 18,700 levels

MARKET UPDATE: Sensex surged over 150 points to trade around 62,988 levels, whereas Nifty50 gained over 50 points to trade above 18,650 levels

MARKET UPDATE: Sensex traded flat at 62,777 levels, whereas Nifty50 was flat above 18,600 levels

Closing Bell: Sensex up 240 points, Nifty at 18593.85

MARKET UPDATE: Sensex rallied over 300 points, whereas Nifty50 gained over 50 points to trade above 18,600 levels

Follow Us On: